Pfizer taps WuXi for new contract studies
This article was originally published in Scrip
WuXi PharmaTech has struck a new three-year contract with Pfizerto conduct in vitro absorption, distribution, metabolism and excretion (ADME) studies. The firms will develop ADME assays to screen and optimise new drug compounds synthesised for Pfizer by WuXi. The Chinese contract research firm already conducts a variety of work for Pfizer, including in the synthetic and medicinal chemistry areas.
You may also be interested in...
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.